FDA to raise fees on Indian drugmakers

(MENAFN) Costs for sale of Indian drugmakers' products in American markets will jump as the US Food and Drug Administration (FDA) will increase fees for drug makers by up to 48 percent starting from October, Saudi Gazette reported. Drug companies are to pay fees to support the costs of reviewing the drugs before approval and for facility inspections. India is the US's second largest drug exporter. Most drugmakers in India manufacture generic versions of drugs and sell at very low prices. Indian drugs hold 10 percent of the US generic drug market.